M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-12-03

AUTHORS

Paul M. McKie, Tomoko Ichiki, John C. Burnett

ABSTRACT

The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function–enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension. More... »

PAGES

62-69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5

DOI

http://dx.doi.org/10.1007/s11906-011-0244-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012051007

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22135207


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aldosterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Natriuretic Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation, Preclinical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glomerular Filtration Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuresis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Renal Circulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sympathetic Nervous System", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Therapies, Investigational", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vasodilation", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McKie", 
        "givenName": "Paul M.", 
        "id": "sg:person.01271304603.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271304603.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ichiki", 
        "givenName": "Tomoko", 
        "id": "sg:person.01100245546.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100245546.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burnett", 
        "givenName": "John C.", 
        "id": "sg:person.01001266776.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-3-540-68964-5_15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002318921", 
          "https://doi.org/10.1007/978-3-540-68964-5_15"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00109-010-0641-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045002962", 
          "https://doi.org/10.1007/s00109-010-0641-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.361", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041461900", 
          "https://doi.org/10.1038/ng.361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.328", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035621233", 
          "https://doi.org/10.1038/ng.328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt0806-942", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032133391", 
          "https://doi.org/10.1038/nbt0806-942"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/378065a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015449350", 
          "https://doi.org/10.1038/378065a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051687311", 
          "https://doi.org/10.1038/nrd2399"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-12-03", 
    "datePublishedReg": "2011-12-03", 
    "description": "The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function\u2013enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11906-011-0244-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021183", 
        "issn": [
          "1522-6417", 
          "1534-3111"
        ], 
        "name": "Current Hypertension Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "keywords": [
      "atrial natriuretic peptide", 
      "renal blood flow", 
      "glomerular filtration rate", 
      "natriuretic peptide", 
      "filtration rate", 
      "blood flow", 
      "higher plasma atrial natriuretic peptide", 
      "plasma atrial natriuretic peptide", 
      "action of ANP", 
      "suppression of aldosterone", 
      "inhibition of aldosterone", 
      "BP-lowering action", 
      "sympathetic nervous system", 
      "blood pressure regulation", 
      "recent human studies", 
      "cardiorenal actions", 
      "systemic vasodilatation", 
      "renal function", 
      "antihypertensive agents", 
      "human hypertension", 
      "BP regulation", 
      "lower risk", 
      "human studies", 
      "hypertension", 
      "nervous system", 
      "animal models", 
      "clinical testing", 
      "pressure regulation", 
      "therapeutic potential", 
      "vasodilatation", 
      "aldosterone", 
      "diuresis", 
      "protein therapy", 
      "multiple mechanisms", 
      "therapy", 
      "inhibition", 
      "peptides", 
      "novel strategy", 
      "concomitant enhancement", 
      "proteolytic degradation", 
      "action", 
      "risk", 
      "role", 
      "association", 
      "regulation", 
      "rate", 
      "suppression", 
      "agents", 
      "fundamental role", 
      "testing", 
      "study", 
      "reduction", 
      "BP", 
      "mechanism", 
      "function", 
      "addition", 
      "enhancement", 
      "development", 
      "strategies", 
      "potential", 
      "characteristics", 
      "flow", 
      "model", 
      "system", 
      "degradation", 
      "properties", 
      "attractive characteristics"
    ], 
    "name": "M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy", 
    "pagination": "62-69", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012051007"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11906-011-0244-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22135207"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11906-011-0244-5", 
      "https://app.dimensions.ai/details/publication/pub.1012051007"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_539.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11906-011-0244-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11906-011-0244-5'


 

This table displays all metadata directly associated to this object as RDF triples.

229 TRIPLES      22 PREDICATES      114 URIs      99 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11906-011-0244-5 schema:about N04aad29dcee34250bab901635354894c
2 N1410a39ca9f941b0b01ca42a47111ca0
3 N15e22f838036478598ede90964fd8d18
4 N315b6c7702584c3ab372cc8359f79139
5 N482ae7294d4c40549b13a9d2b0d86a5b
6 N755a875f5fe7425d98cae38740db3532
7 N8138c9cb6a0644a5b7c3b89795df9a00
8 Nad36b2f323b04846864419f235238d65
9 Nc15094fc585c4fdc88f7e63e45d57118
10 Nc5afa7d931bb4daebf4cc3a70f4131db
11 Nc5ff97a633bf46ad8753f02cd25d5ba1
12 Nd0a95521caa04bec8ef70e091b166b9c
13 Nd3858da97cd4452d8932e43d2d15ae4e
14 Nf429b4c102d84f42a8237ca7c74d7466
15 anzsrc-for:11
16 anzsrc-for:1102
17 schema:author N207320efbbf144adb71dcc36d4419412
18 schema:citation sg:pub.10.1007/978-3-540-68964-5_15
19 sg:pub.10.1007/s00109-010-0641-2
20 sg:pub.10.1038/378065a0
21 sg:pub.10.1038/nbt0806-942
22 sg:pub.10.1038/ng.328
23 sg:pub.10.1038/ng.361
24 sg:pub.10.1038/nrd2399
25 schema:datePublished 2011-12-03
26 schema:datePublishedReg 2011-12-03
27 schema:description The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function–enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N5605e0d67484480d84822bc6b5054c52
32 N5bbaec63ca8647b69b5e3c8fbeed65ba
33 sg:journal.1021183
34 schema:keywords BP
35 BP regulation
36 BP-lowering action
37 action
38 action of ANP
39 addition
40 agents
41 aldosterone
42 animal models
43 antihypertensive agents
44 association
45 atrial natriuretic peptide
46 attractive characteristics
47 blood flow
48 blood pressure regulation
49 cardiorenal actions
50 characteristics
51 clinical testing
52 concomitant enhancement
53 degradation
54 development
55 diuresis
56 enhancement
57 filtration rate
58 flow
59 function
60 fundamental role
61 glomerular filtration rate
62 higher plasma atrial natriuretic peptide
63 human hypertension
64 human studies
65 hypertension
66 inhibition
67 inhibition of aldosterone
68 lower risk
69 mechanism
70 model
71 multiple mechanisms
72 natriuretic peptide
73 nervous system
74 novel strategy
75 peptides
76 plasma atrial natriuretic peptide
77 potential
78 pressure regulation
79 properties
80 protein therapy
81 proteolytic degradation
82 rate
83 recent human studies
84 reduction
85 regulation
86 renal blood flow
87 renal function
88 risk
89 role
90 strategies
91 study
92 suppression
93 suppression of aldosterone
94 sympathetic nervous system
95 system
96 systemic vasodilatation
97 testing
98 therapeutic potential
99 therapy
100 vasodilatation
101 schema:name M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy
102 schema:pagination 62-69
103 schema:productId N21fadb4eaf444aec942d9e91ac901965
104 Na6435c09ae654b9cbd309b698a06fa95
105 Nc3a31b01f7ec448e9bf970b00c87a741
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012051007
107 https://doi.org/10.1007/s11906-011-0244-5
108 schema:sdDatePublished 2022-06-01T22:08
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N45e1fddb374b47d9a44b1098ac87a4c6
111 schema:url https://doi.org/10.1007/s11906-011-0244-5
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N04aad29dcee34250bab901635354894c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Drug Evaluation, Preclinical
117 rdf:type schema:DefinedTerm
118 N1410a39ca9f941b0b01ca42a47111ca0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Glomerular Filtration Rate
120 rdf:type schema:DefinedTerm
121 N15e22f838036478598ede90964fd8d18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 N207320efbbf144adb71dcc36d4419412 rdf:first sg:person.01271304603.22
125 rdf:rest N519a6ff94c2443b18ed56e9a345e2b6d
126 N21fadb4eaf444aec942d9e91ac901965 schema:name pubmed_id
127 schema:value 22135207
128 rdf:type schema:PropertyValue
129 N315b6c7702584c3ab372cc8359f79139 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Atrial Natriuretic Factor
131 rdf:type schema:DefinedTerm
132 N45e1fddb374b47d9a44b1098ac87a4c6 schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 N482ae7294d4c40549b13a9d2b0d86a5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Vasodilation
136 rdf:type schema:DefinedTerm
137 N519a6ff94c2443b18ed56e9a345e2b6d rdf:first sg:person.01100245546.46
138 rdf:rest Na866e9c7b07545a6b3897269c01ee55d
139 N5605e0d67484480d84822bc6b5054c52 schema:volumeNumber 14
140 rdf:type schema:PublicationVolume
141 N5bbaec63ca8647b69b5e3c8fbeed65ba schema:issueNumber 1
142 rdf:type schema:PublicationIssue
143 N755a875f5fe7425d98cae38740db3532 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Renal Circulation
145 rdf:type schema:DefinedTerm
146 N8138c9cb6a0644a5b7c3b89795df9a00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Blood Pressure
148 rdf:type schema:DefinedTerm
149 Na6435c09ae654b9cbd309b698a06fa95 schema:name doi
150 schema:value 10.1007/s11906-011-0244-5
151 rdf:type schema:PropertyValue
152 Na866e9c7b07545a6b3897269c01ee55d rdf:first sg:person.01001266776.01
153 rdf:rest rdf:nil
154 Nad36b2f323b04846864419f235238d65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Biological Availability
156 rdf:type schema:DefinedTerm
157 Nc15094fc585c4fdc88f7e63e45d57118 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Antihypertensive Agents
159 rdf:type schema:DefinedTerm
160 Nc3a31b01f7ec448e9bf970b00c87a741 schema:name dimensions_id
161 schema:value pub.1012051007
162 rdf:type schema:PropertyValue
163 Nc5afa7d931bb4daebf4cc3a70f4131db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Aldosterone
165 rdf:type schema:DefinedTerm
166 Nc5ff97a633bf46ad8753f02cd25d5ba1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Therapies, Investigational
168 rdf:type schema:DefinedTerm
169 Nd0a95521caa04bec8ef70e091b166b9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Natriuresis
171 rdf:type schema:DefinedTerm
172 Nd3858da97cd4452d8932e43d2d15ae4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Hypertension
174 rdf:type schema:DefinedTerm
175 Nf429b4c102d84f42a8237ca7c74d7466 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Sympathetic Nervous System
177 rdf:type schema:DefinedTerm
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
182 schema:name Cardiorespiratory Medicine and Haematology
183 rdf:type schema:DefinedTerm
184 sg:journal.1021183 schema:issn 1522-6417
185 1534-3111
186 schema:name Current Hypertension Reports
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.01001266776.01 schema:affiliation grid-institutes:grid.66875.3a
190 schema:familyName Burnett
191 schema:givenName John C.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01
193 rdf:type schema:Person
194 sg:person.01100245546.46 schema:affiliation grid-institutes:grid.66875.3a
195 schema:familyName Ichiki
196 schema:givenName Tomoko
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100245546.46
198 rdf:type schema:Person
199 sg:person.01271304603.22 schema:affiliation grid-institutes:grid.66875.3a
200 schema:familyName McKie
201 schema:givenName Paul M.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271304603.22
203 rdf:type schema:Person
204 sg:pub.10.1007/978-3-540-68964-5_15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002318921
205 https://doi.org/10.1007/978-3-540-68964-5_15
206 rdf:type schema:CreativeWork
207 sg:pub.10.1007/s00109-010-0641-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045002962
208 https://doi.org/10.1007/s00109-010-0641-2
209 rdf:type schema:CreativeWork
210 sg:pub.10.1038/378065a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015449350
211 https://doi.org/10.1038/378065a0
212 rdf:type schema:CreativeWork
213 sg:pub.10.1038/nbt0806-942 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032133391
214 https://doi.org/10.1038/nbt0806-942
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/ng.328 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035621233
217 https://doi.org/10.1038/ng.328
218 rdf:type schema:CreativeWork
219 sg:pub.10.1038/ng.361 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041461900
220 https://doi.org/10.1038/ng.361
221 rdf:type schema:CreativeWork
222 sg:pub.10.1038/nrd2399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051687311
223 https://doi.org/10.1038/nrd2399
224 rdf:type schema:CreativeWork
225 grid-institutes:grid.66875.3a schema:alternateName Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA
226 Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA
227 schema:name Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA
228 Mayo Clinic, Division of Cardiovascular Diseases, 200 First Street SW, 55905, Rochester, MN, USA
229 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...